Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.92 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 5/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triethylene Glycol SCHEMBL197304 | 1.00 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Triethylene Glycol SCHEMBL11552982 | 1.00 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Tetraethylene Glycol SCHEMBL379094 | 1.00 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Triethylene Glycol SCHEMBL43068 | 1.00 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Triethylene Glycol SCHEMBL28268117 | 0.96 | MEN1 (0.85) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL5145873 | 0.96 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL12157423 | 0.96 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL12865309 | 0.96 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL4092706 | 0.96 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| Di(Hydroxyethyl)Ether SCHEMBL2029350 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449419-B1 | Hydroxy terminated polyamides | TEXACO CHEMICAL (US) | 1994-08-10 | — | — | EP | claimed |
| US-5130382-A | Amine terminated polyethers reacted with a diacid to form hydroxy terminated polyamides for forming polyurethanes | TEXACO CHEMICAL COMPANY (US) | 1992-07-14 | — | — | US | claimed |
| EP-0449419-A1 | Hydroxy terminated polyamides | Huntsman Corporation (US) | 1991-10-02 | — | — | EP | claimed |
| EP-4199179-B1 | POSITIVE ELECTRODE ACTIVE MATERIAL, POSITIVE ELECTRODE AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | LG ENERGY SOLUTION LTD (KR) | 2026-03-11 | — | — | EP | disclosed |
| US-20230361302-A1 | POSITIVE ELECTRODE ADDITIVE FOR LITHIUM SECONDARY BATTERY, POSITIVE ELECTRODE ACTIVE MATERIAL COMPRISING SAME, POSITIVE ELECTRODE, AND LITHIUM SECONDARY BATTERY | LG ENERGY SOLUTION, LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| EP-4199179-A1 | POSITIVE ELECTRODE ADDITIVE FOR LITHIUM SECONDARY BATTERY, POSITIVE ELECTRODE ACTIVE MATERIAL COMPRISING SAME, POSITIVE ELECTRODE, AND LITHIUM SECONDARY BATTERY | LG Energy Solution, Ltd. (KR) | 2023-06-21 | — | — | EP | disclosed |
| CN-115353616-B | Pegylated lipid | 厦门赛诺邦格生物科技股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115515924-A | Cationic lipid, liposome containing cationic lipid, nucleic acid pharmaceutical composition containing liposome, preparation and application thereof | 厦门赛诺邦格生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-109651275-B | Triazine compound, composition and preparation method thereof | 江苏裕事达新材料科技有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115353616-A | Pegylated lipid | 厦门赛诺邦格生物科技股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-113402405-B | Cationic lipid, liposome containing cationic lipid, nucleic acid pharmaceutical composition containing liposome, preparation and application thereof | 厦门赛诺邦格生物科技股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-5082924-A | Polyamide-ester from polyethylene glycol monoamine and catalytic process therefor | TEXACO CHEMICAL COMPANY (US) | 1992-01-21 | — | — | US | disclosed |
| EP-0462644-A1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0449419-A1 | Hydroxy terminated polyamides | Huntsman Corporation (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0437981-A1 | Polyamide-esters, processes for the manufacture thereof and intermediates therefor | TEXACO CHEMICAL COMPANY (US) | 1991-07-24 | — | — | EP | disclosed |
| US-5030754-A | Hydroxy-terminated substituted diurea derivatives | TEXACO CHEMICAL COMPANY (US) | 1991-07-09 | — | — | US | disclosed |
| US-4996315-A | Reacting polyalkylene glcyol monoamines with dicarboxylic acids in a 1:1 molar ratio | TEXACO CHEMICAL COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0160047-A1 | PROCESS FOR THE REVERSIBLE TRANSFER OF THERMAL ENERGY AND HEAT TRANSFER SYSTEM USEFUL THEREIN | BUTLER, Robert Floyd (US) | 1985-11-06 | — | — | EP | disclosed |
| US-4524759-A | Process for the reversible transfer of thermal energy and heat transfer system useful therein | HAYCOCK, WILLIAM T. | 1985-06-25 | — | — | US | disclosed |
| WO-1985002010-A1 | PROCESS FOR THE REVERSIBLE TRANSFER OF THERMAL ENERGY AND HEAT TRANSFER SYSTEM USEFUL THEREIN | BUTLER ROBERT FLOYD | 1985-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230361302-A1 | POSITIVE ELECTRODE ADDITIVE FOR LITHIUM SECONDARY BATTERY, POSITIVE ELECTRODE ACTIVE MATERIAL COMPRISING SAME, POSITIVE ELECTRODE, AND LITHIUM SECONDARY BATTERY | CACNA2D1, CACNA2D2, CACNA1S | MEN1 1060/4885KMT2A 1985/4885TSHR 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.